Abstract:Hongwei Huang, &ast Wei Liao, &ast Kaiyue Zhang, Hao Wang, Qi Cheng, Bin Mei Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China &astThese authors contributed equally to this work Correspondence: Bin Mei; Qi Cheng, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jie Fang Avenue, Qiaokou, Wuhan, 430030, People's Republic of China, Email ; Purpose: The prognosis of patients with huge hepatocellular carcinoma (huge HCC, diameter ≥ 10 cm) is poor owing to the high early recurrence rate. This study aimed to explore the clinical value of postoperative adjuvant transarterial chemoembolization (PA-TACE) plus programmed cell death-1 (PD-1) inhibitors for huge HCC. Patients and Methods: Data from consecutive huge HCC patients treated with hepatectomy during June 2017 and July 2022 were retrospectively collected. Baseline differences were balanced between huge HCC patients who underwent PA-TACE with (AIT group) or without PD-1 inhibitors (AT group) by propensity-score matching (PSM). We compared recurrence-free survival (RFS), overall survival (OS) and recurrence patterns between the two groups. Independent risk factors for RFS and OS were confirmed by Cox regression analysis, and subgroup analysis was also conducted. Results: A total of 294 patients were enrolled, and 77 pairs of patients in the AIT and AT groups were matched by PSM. The 1-year and 2-year RFS were 49.9% and 35.7% in the AIT group compared to 24.7% and 15.5% in the AT group respectively (p< 0.001). The 1-year and 2-year OS were 83.6% and 66.9% in the AIT group compared to 50.6% and 36.8% in the AT group respectively (p< 0.001). There were no significant differences in recurrence patterns between the two groups. Multivariable analysis demonstrated that combined therapy of PA-TACE plus PD-1 inhibitors was a protective factor related to both RFS and OS. Conclusion: PA-TACE plus PD-1 inhibitors could improve survival outcomes for huge HCC patients. Keywords: hepatocellular carcinoma, postoperative adjuvant therapy, programmed cell death-1 inhibitors, transarterial chemoembolization, early recurrence Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for 75–86% of cases. 1 Many HCC patients were diagnosed with huge sizes (exceeding 10 cm in diameter) owing to insidious symptoms and lacking of well-organized screening programs. 2,3 Although hepatectomy demonstrated quite high feasibility and cost-effectiveness and was the only curative treatment for huge HCC, the oncological outcomes were still poor for early recurrence following surgery. 4,5 The recurrence rates remained as high as 32.1–54% at 1 year and 57–70% at 3 years. 2,3,6,7 Therefore, postoperative adjuvant treatment is necessary to reduce early recurrence rate and improve oncological prognosis for patients with huge HCC. Postoperative adjuvant treatment includes locoregional treatments such as transarterial chemoembolization (TACE), hepatic artery infusion chemotherapy, radiotherapy, and systemic therapy such as antiviral treatment, tyrosine kinase inhibitors (TKIs), and immune checkpoint inhibitors (ICIs). 8–12 Up to date, postoperative adjuvant TACE (PA-TACE) has demonstrated its importance in reducing recurrence rate, improving recurrence-free survival (RFS) and overall survival (OS) for HCC patients with high recurrence risks, including huge HCC. 8,13,14 Therefore, PA-TACE was recommended in guidelines of China. However, the effect of PA-TACE is still unsatisfactory. TACE, as a kind of locoregional treatment, can be used in combination with systemic therapy to further improve oncological prognosis of HCC. ICIs are being explored as postoperative adjuvant treatment for HCC in several Phase III clinical trials, such as EMERALD-2, KEYNOTE-937, IMbrave 050, CheckMate 9DX. Recently, ICIs were recommended as adjuvant therapy for patients with HCC by the latest guidelines of American Association for the Study of Liver Diseases (AASLD) according to the interim results of IMbrave 050 which showed that adjuvant atezolizumab plus bevacizumab was associated with significantly improved RFS compared with active surveillance (1-year RFS, 78% vs 65%). 15,16 However, to the best of our knowledge, there is still no study about PA-TACE plus adjuvant immunotherapy for huge HCC. In this study, two cohorts were established according to different postoperative adjuvant treatments. All included patients with huge tumor underwent R0 hepatectomy. The short-term oncological outcomes of the two methods were compared, -Abstract Truncated-

PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis

Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate‐stage Hepatocellular Carcinoma: A Multicenter Retrospective Study

Adjuvant Transarterial Chemoembolization Plus Immunotherapy for Huge Hepatocellular Carcinoma: A Propensity Score Matching Cohort Study

Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma

The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study

Transarterial Chemoembolization Combined with Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study

Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors

The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study

Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study

The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma.

Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib Plus Humanized Programmed Death Receptor-1 in Patients with High-Risk Advanced Hepatocellular Carcinoma: A Real-World Study

Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma

Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC

Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study

Transarterial Chemoembolization With/without Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: a Single Center, Propensity Score Matching Real-World Study